Clinical Characteristics and Treatment Outcome of Waldenstrom Macroglobulinemia: Experience from a Tertiary Cancer Centre

Background: Waldenstroms macroglobulinemia (WM) or Lymphoplasmacytic lymphoma is a rare B cell lymphoproliferative malignancy characterized by serum monoclonal immunoglobulin M (IgM) protein and lymphoplasmacytic infiltration in the bone marrow. Patients usually present in their seventh decade with symptoms related to the infiltration of the marrow or the effects of monoclonal IgM in the blood. Objective: Was to study the clinical characteristics and treatment outcome of patients diagnosed with WM. Materials and methods: This is a retrospective analysis of 26 cases of WM treated at a tertiary cancer centre. Results: WM constituted 0.68% of our nonHodgkin’s lymphoma. The median age at presentation was 67 years with a male to female ratio of 2:1. Four patients had lymphadenopathy, six had splenomegaly and four patients had evidence of hyper viscosity. All patients had IgM paraproteinemia, the M band was IgM-kappa in 19 patients and IgM-lambda in seven patients. All patients had a histopathological confirmation. According to IPSS-WM, 12 patients each were in the intermediate and high risk group and 2 in the low risk group. Among the 26 patients, 20 patients received upfront treatment and four patients were kept under observation. The indications for treatment were cytopenia in ten patients, constitutional symptoms in five, hyper viscosity in four and symptomatic lymphadenopathy in one patient. Sixteen patients received rituximab-based chemotherapy. Four patients with features with hyper viscosity underwent plasmapheresis. The three year progression free survival and overall survival were 69.4% and 78 % respectively. Conclusions: WM is a low grade B cell lymphoproliferative disorder having an indolent course and do not require treatment for prolonged period. Diagnosis is challenging due to lack of distinct diagnostic features. Rituximab containing regimens are the standard of care. Newer targeted treatment options may improve the outcome of this incurable disease.

 Introduction

Waldenstroms macroglobulinemia (WM) or Lymphoplasmacytic lymphoma (LPL) is a rare B cell lymphoproliferative malignancy which accounts for accounts for 1.9% of all non Hodgkin’’s lymphoma (NHL). [1]. It is characterized by monoclonal immunoglobulin M (IgM) serum protein and monoclonal lymphoplasmacytic cells in the bone marrow. It is a disease of the elderly, with a median age at diagnosis of 73 years [1]. It is an indolent disease with a median survival ranging from 5 to 10 years or more [2, 3].

Monoclonal gammopathy is an incidental finding seen in about 3.5% of individuals above 50 years of age and WM is an important differential diagnosis of monoclonal gammopathy [4].

The disease presents with symptoms related to the infiltration of bone marrow by small lymphoid cells and the elevated serum IgM paraprotein which produces hyperviscosity and autoimmune phenomena [5, 6].

WM is a diagnosis of exclusion and made only after excluding other small B cell neoplasms. The most important risk factor for developing WM is a preexisting IgM monoclonal gammopathy of undetermined significance (MGUS) which can transform to WM at a rate of 1.5% per year [7].

In this report we present the results of a retrospective analysis of 26 cases of WM treated at a tertiary cancer centre.

 Materials and Methods

This is a retrospective study conducted in the Department of Medical Oncology at a tertiary cancer centre in India during a seven-year period (January 2013 to December 2019). Patients with WM above 14 years of age diagnosed during the study period were included. Twenty-six patients were diagnosed with WM during the study period. The study was approved by the Human ethics Committee (HEC No. 40/22). All procedures were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration.

<italic id="italic-1">Inclusion/ Exclusion Criteria<italic id="italic-2"/></italic>

Eligibility criteria included all patients aged above 14 years with a histological diagnosis of WM/LPL. Patients with relapsed WM and who received some prior treatments were excluded from the study.

 <italic id="italic-edee02e18e126120c9dd9f7ca19bc534">Methodology<italic id="italic-12876f0555e92df55d36075c49121798"/></italic>

Medical records of patients were studied with respect to the demographic details, clinical history, and physical examination, complete hemogram, serum chemistries, beta 2 microglobulin and serum lactate dehydrogenase (LDH). Diagnostic work up including immunoglobulin assay, serum protein electrophoresis (SPE), immunofixation electrophoresis (IFE), serum viscosity, histopathology, bone marrow study, and imaging studies were noted. International prognostic staging for WM (IPSS-WM) was used for staging [3]. The standard treatment for WM included systemic chemo-immunotherapy with the anti-CD 20 monoclonal antibody rituximab and other chemotherapy drugs in varying combinations for 6 cycles. Plasmapheresis or plasma exchange was considered for patients with evidence of hyper viscosity. The treatment responses were obtained at regular intervals during chemotherapy, by end of chemotherapy, at relapse and while on follow up. Clinical response was classified as complete response (CR), Very Good Partial Response (VgPR), partial response (PR), stable disease (SD), and progressive disease (PD) based on response criteria adopted at the 6th International Workshop on WM [8]. Overall survival (OS) was assessed from the initiation of definitive chemotherapy to the last follow up or death and progression free survival (PFS) was calculated from the initiation of chemotherapy till disease progression.

<italic id="italic-f5cbb1e0823b7a000d93e9f39faaf9ee">Statistical analysis<italic id="italic-105d7f041908bedc6c4cbb2d9ba31aa3"/></italic>

The baseline patient characteristics, treatment and response details were analyzed using descriptive statistics. OS and PFS were assessed by Kaplan – Meier method, using SPSS v. 11. The risk for OS and PFS were analysed using Cox regression method. Statistical significance was defined as a p value < 0.05.

 Results

Baseline patient characteristics are described in Table 1.

Baseline patient characteristics (n=26) Frequency, n (%)
Median age (years) 67 (range 42-88)
Age > 65 years 18 (69 %)
M: F ratio 2:01
B symptoms 10 (38)
The median duration of symptoms (weeks) 12 (range 1 – 24)
Lymphadenopathy 4 (15)
Splenomegaly 4 (15)
Hyper viscosity (> 4 centipoise) 4 (15)
Hb < 10 g/ dL 13 (50)
Platelet count< 100000/mm3 04 (15)
Elevated LDH 13 (50)
Elevated Beta 2 macroglobulin 14 (54)
M band > 4 g/dL 6 (23)
IFE: IgM-kappa 19 (73)
IgM-Lambda 7 (27)
IPSS –WP scoring  
Low risk 2 (7.7)
Intermediate risk 12 (46.15)
High risk 12 (46.15)

n, number of patients; M:F ratio, Male: Female ratio, B symptoms, fever/weight loss/night sweats; Hb, Hemoglobin; LDH, Lactate Dehydrogenase; M band, Monoclonal band in serum protein electrophoresis; IFE, Immunofixation Electrophoresis. IPSS International prognostic staging system for WM

During the period 2013 to 2019, 3819 cases of NHL above 14 years of age were treated in our department, of which 26 were WM (0.68%). The median age at presentation was 67 years (range 42-88 years). There were 18 males and 9 females, with the male to female ratio of 2:1. Only two patients were less than 60 years of age (8%) and elderly patients above>65 years constituted 2/3rd (17 patients) of our study population. The most common presenting symptoms were dyspnea on exertion, fatigue, and low backache. One patient each presented with abdominal discomfort, neck swelling, recurrent urinary tract infection, lower limb pain, jaundice and fever. B symptoms were present in 10 patients (38%). The median duration of symptoms was 12 weeks (range 1 – 24 weeks). Four patients had lymphadenopathy (15%), six had splenomegaly (23%) and four patients (15%) had evidence of hyper viscosity at presentation. The mean hemoglobin in the study population was 9.5 g/dL (range 5.6- 15.3g/dL) and four patients had thrombocytopenia less than 100000/mm3 (range 14000-602000/mm3). The mean serum viscosity was 3.5 centipoises (range 1.7- 7.3). Among our patients, one tested positive for tuberculosis. All patients had IgM paraproteinemia on SPE with a median monoclonal band (M band) of 2.6 gm/dL (range 0.8 - 5.9 gm/dL). On IFE the M band was IgM-kappa (IgM-k) in 19 patients and IgM-lambda (IgM-λ) in seven patients. Serum LDH was elevated in 13 patients (50%) and serum beta 2 microglobulin was >4 mg/L in 14 patients (54%).

All patients had a histopathological confirmation either from bone marrow or from a lymph node biopsy. Histopathological examination of bone marrow specimens showed infiltration by plasmacytoid cells in variable numbers mixed with frequent reactive mast cells. On immunohistochemically (IHC) the tumor cells were positive for CD20, surface IgM, CD 138 and negative for CD5, CD10, CyclinD1. Tumor cells showed either k or λ light chain restriction (Figure 1 a,b,c,d).

According to IPSS-WM, 12 patients each were in the intermediate and high risk group and 2 in the low risk group.

<italic id="italic-85ffcefaa22cbea03a6ea8c09b7a58e2">Treatment<italic id="italic-d40aa0d5c0332e6cde0e10ed70d69105"/></italic>

Among the 26 patients, 20 (77%) patients received upfront treatment and two patients refused treatment. Treatment details are summarized in Table 2.

Treatment outcome RCD BR BRD RCHOP/RCVP Rituximab single agent Others Total number
Number of patients 6 3 3 2 2 4 20
Complete remission 4 3 2 2 1 1 13
Partial remission 0 0 0 0 1 1 2
Progressive disease 1 0 0 0 0 0 1
Death 0 0 0 0 0 1 1
Relapse 0 0 1 0 1 1 3
Defaulted 1 0 1 0 0 1 3

RCD, Rituximab + cyclophosphamide + dexamethasone; BR, Bendamustine + Rituximab; BRD, Bortezomib +rituximab + dexamethasone; R-CHOP/RCVP, Rituximab + Cyclophosphamide + Vincristine + doxorubicin + Prednisolone/ Rituximab + Cyclophosphamide + Vincristine + Prednisolone.

Four patients with WM had no constitutional symptoms, no anemia, no symptoms attributable to IgM monoclonal protein or tumor infiltration at the time of presentation. These patients were diagnosed with smoldering WM and were followed up for disease progression. Three patients remained asymptomatic on regular follow up and one received systemic chemotherapy on progression after four years.

Among twenty patients who received upfront treatment the indications for treatment were cytopenia in ten patients, constitutional symptoms in five, hyper viscosity in four and symptomatic lymphadenopathy in one patient. The treatment received were rituximab + cyclophosphamide + dexamethasone (RCD) in six, bendamustine + rituximab (BR) in three, bortezomib +rituximab + dexamethasone (BRD) in three, single agent rituximab in two, R-CHOP/ RCVP in two, cyclophosphamide + prednisolone (EP) in two, thalidomide + dexamethasone (TD) in one, bortezomib + dexamethasone (BD) in one patient. Sixteen patients received rituximab-based chemotherapy. Four patients with features with hyper viscosity underwent plasmapheresis.

Of the twenty patients who took treatment 13 patients (65%) attained CR, two (10%) attained PR, one patient (5%) progressed. One patient (5%) died during chemotherapy and three patients (15%) discontinued treatment. The patient who progressed on first line chemotherapy received BR as second line treatment and died while on chemotherapy. Three patients had relapsed with a median DFS of 12 months and received second line treatment with RCD/ BR/ lenalidomide + dexamethasone. The patient who received RCD as second line chemotherapy attained CR, relapsed again after 24 months for which she received BRD and continues to be in remission at 30 months. The other two patients defaulted treatment, One patient developed lung cancer at 88 months of follow up and another patient contracted COVID 19 infection and died due to COVID pneumonia.

<italic id="italic-3">Survival (Figure 2)<italic id="italic-4"/></italic>

The PFS at 3 years was 69.4%. There was a significant difference in PFS with respect to presence of B symptoms, platelet count and monoclonal protein level in SPE.

The 3-year OS was 78 %. OS for patients with age group < 65 years was 85.7 % and > 65 years was 75 with a P value of 0.47. There was no significant difference in OS with respect to age, sex, B symptoms, hemoglobin level, platelet count, serum LDH, monoclonal protein level in SPE, beta2 microglobulin (Table 3).

Variables   PFS       OS    
  P-value Hazard ratio (HR) 95% CI for HR   P value Hazard Ratio 95% CI for HR  
      Lower Upper     Lower Upper
Age 0.677 0.737 0.175 3.098 0.488 2.142 0.249 18.391
< 65 v/s > 65 years                
Sex 0.677 1.357 0.323 5.701 0.488 0.467 0.054 4.009
Male v/s Female                
B symptoms 0.175 0.018 0 5.918 0.27 0.022 0 19.603
Hemoglobin (g/dL) 0.667 1.371 0.326 5.769 0.271 3.345 0.39 28.717
>10 v/s < 10                
Platelet Count (mm)3 0.068 3.869 0.905 16.528 0.091 4.039 0.799 20.424
1 lakh v/s <1 lakh                
M Protein (g/dL) 0.046 4.602 1.026 20.637 0.19 3.481 0.539 22.48
<4 v/s > 4                
IFE 0.266 0.304 0.037 2.48 0.955 1.05 0.192 5.749
IgM-k v/s IgM-λ                
Beta 2Microglobulin (g/dL) 0.542 1.92 0.236 15.625 0.516 0.567 0.102 3.146

PFS, progression free survival; OS, Overall survival; CI, Confidence Interval; B symptoms, fever/weight loss/night sweats; M protein, Monoclonal band in serum protein electrophoresis; IFE, Immunofixation Electrophoresis; IgM-k, Immunoglobulin M- kappa; IgM- λ, Immunoglobulin M-Lambda.

The three-year OS was 75% in the group of patients who received rituximab+/- chemotherapy versus 50 % in the non-rituximab arm with a P value of 0.8.

 Discussion

Waldenstrom macroglobulinemia or lymphoplasmacytic lymphoma is an extremely rare neoplasm. The disease was first described by Jan G. Waldenstrom in 1944, who reported an unusual presentation of lymphadenopathy, anaemia, bleeding, raised ESR, hyperviscosity and IgM hypergammaglobulinemia [9-11]. It is usually seen in the seventh or eighth decade of life with a male predominance. WM and LPL overlap, the only differentiating criteria being presence of IgM paraprotein in WM. In our study, WM constituted 0.68% of NHL with a median age at diagnosis of 67 years and male predominance.

The diagnosis of WML is usually challenging. About 25% of patients are asymptomatic at diagnosis, with 40% to 70% developing symptomatic disease within 3 years and 10 years of diagnosis [12]. The symptoms are caused by neoplastic infiltration of organs and elevated levels of IgM paraprotein. Patients usually present with constitutional symptoms like fatigue, fever, weight loss [13]. About one third of patients present with anaemia due to decreased erythropoiesis because of bone marrow infiltration, decreased erythrocyte survival due to IgM associated hemolysis, low erythropoietin levels, and iron deficiency [14]. Lymphadenopathy and or hepatosplenomegaly is seen in about 25% of cases and some may present with involvement extranodal sites such as skin, stomach, bowel etc [9,15-18]. WM can present with hyperviscosity symptoms in 30%, autoimmune hemolysis seen in 20%, coagulopathy and or diarrhoea. Symptoms related to hyperviscosity include headache, visual disturbances, neurologic symptoms and bleeding. Precipitation of IgM paraproteins can result in cryoglobulinemia causing Raynaud phenomena and cold urticaria [10, 19]. The autoimmue hemolysis is caused by cold agglutinins [12,16-18]. In the present study, 38% had constitutional symptoms, 50% had anaemia, 15% each had thrombocytopenia, lymphadenopathy, hepatosplenomegaly and symptoms of hyperviscosity. All our patients had a histological diagnosis of WM, 73% had IgM kappa and 27% had IgM lambda disease.

The 2017 WHO classification of tumors of hematopoietic and lymphoid tissues have established four diagnostic criteria for WM [11].

1. Presence of IgM monoclonal gammopathy

2. Infiltration of bone marrow by small lymphocytes showing plasmacytoid or plasma cell differentiation.

3. Bone marrow infiltration showing an intertrabecular pattern.

4. Immunophenotype supportive of WM/LPL including surface IgM+, CD19+, CD20+, CD22+, CD25+, CD27+, FMC7+, CD5 variable, CD10 -, CD23-, CD103-, CD108-

Most WM/LPL patients have monoclonal IgM, a minority can have both IgM and IgG.

The IPSS-WM is the most well developed and validated tool for risk stratification of symptomatic WM patients [3]. The staging system is based on five common clinical characteristics: age >65 years, haemoglobin ≤ 11.5gm/dL, platelets ≤ 100x109/L, β2 microglobulin>3mg/L, serum IgM > 7gm/dL. Low risk disease is defined as one or less adverse factor and age ≤ 65 years; intermediate risk disease defined as two adverse factors and age > 65 years; and high risk disease defined as having three or more adverse factors. Kastritis reported modified IPSS-WM system including LDH also as a risk factor to delineate high risk patients with a median survival of less than 3years [20]. Sex, B symptoms, IgM value, performance status, presence of hyperviscosity, bone marrow infiltration, and cytogenetic changes have also been reported as risk factors [21]. Rarely, WM can transform into an aggressive immunoblastic variant or a high grade lymphoma [11,19]. The most common genetic event in WM is an acquired mutation affecting the MYD88 gene is reported in 90% of patients. A second mutation affecting CXCR4 gene occurs in one third cases [22]. As per the IPSS- WP scoring, intermediate and high risk constituted 46.15% each and low risk constituted 7.7% in our patient group.

Management of WM is similar to other indolent small B cell lymphomas. Current therapeutic options in WM do not result in cure. The goal of treatment in symptomatic WM is to keep the disease under control as long as possible without impairing the quality of life. Treatment depends on patient symptoms and extent of end organ involvement. Patients with asymptomatic WM are managed by close observation. In symptomatic patients, the treatment of choice is to combine rituximab and chemotherapy [23]. Low risk symptomatic patients can be managed with single agent rituximab [24]. A combination of rituximab and bendamustine (BR) or cyclophosphamide and dexamethasone (DRC) is usually recommended [25,26]. The combination BR when compared to R CHOP showed statistically significant improvement in PFS (69.5 months versus 31.2 months) [26,27]. Rituximab monotherapy is considered in patients with poor general condition [28]. Ibrutinib has been approved as first line in patients not suitable for rituximab/ chemotherapy and in those with recurrences and those refractory to rituximab [29-31]. Bone marrow transplant is reserved for younger patients with extensive bone marrow involvement. If symptoms of hyperviscosity is present, plasmapheresis is recommended prior to chemotherapy [16, 32-34]. Eighty percent of the patients who were given systemic treatment received rituximab based chemotherapy in the present study.

The median survival of patients with WM is about 7.4 years, mortality is associated with symptomatic disease, whereas asymptomatic patients have survival similar to the general population [33]. The 5 year survival rates for IPSS-WM low risk, intermediate risk and high risk are 87%,68% and 36% respectively [3]. The absence of MYD 88 mutation is associated with poor outcome. WM that transforms to diffuse large B cell lymphoma is also associated with poor survival [5,17,19,33, 35]. In the present study, the 3 year PFS was 69.4% and OS was 78%.

In conclusion, WM is a low grade B cell lymphoproliferative disorder having an indolent course and do not require treatment for prolonged period. Diagnosis is challenging due to lack of distinct diagnostic features. Rituximab containing regimens are the standard of care. Newer targeted treatment options may improve the outcome of this incurable disease.

 Acknowledments

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for- profit sectors. The authors declare no conflict of interest

References

01 15 08 3793-3800 118 2012 10.1002/cncr.26627 Wang H Chen Y Li F Delasalle K Wang J Alexanian R Kwak L et al Cancer Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study 01 7 03 1564-1577 23 2005 10.1200/JCO.2005.03.144 Dimopoulos MA Kyle RA Anagnostopoulos A Treon SP Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology Diagnosis and management of Waldenstrom's macroglobulinemia 30 18 04 4163-4170 113 2009 10.1182/blood-2008-08-174961 Morel P Duhamel A Gobbi P Dimopoulos MA Dhodapkar MV McCoy J Crowley J et al Blood International prognostic scoring system for Waldenstrom macroglobulinemia 03 44 11 745-751 114 2017 10.3238/arztebl.2017.0745 Grunenberg A Buske C Deutsches Arzteblatt International Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia 5 09 301-319 29 2015 10.1016/j.blre.2015.03.001 Kapoor P Paludo J Vallumsetla N Greipp PR Blood Reviews Waldenström macroglobulinemia: What a hematologist needs to know 257-282 2004 10.1182/asheducation-2004.1.257 Gertz MA Merlini G Treon SP Hematology. American Society of Hematology. Education Program Amyloidosis and Waldenström's macroglobulinemia 1 03 19-22 9 2009 10.3816/CLM.2009.n.003 McMaster ML Kristinsson SY Turesson I Björkholm M Landgren O Clinical Lymphoma & Myeloma Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia 1 02 68-73 11 2011 10.3816/CLML.2011.n.010 Treon SP Merlini G Morra E Patterson CJ Stone MJ Clinical Lymphoma, Myeloma & Leukemia Report from the Sixth International Workshop on Waldenström's Macroglobulinemia 4 04 346-354 90 2015 10.1002/ajh.23922 Gertz MA American Journal of Hematology Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management 4 04 580-585 137 2013 10.5858/arpa.2012-0034-RS Naderi N Yang DT Archives of Pathology & Laboratory Medicine Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia 19 20 05 2375-2390 127 2016 10.1182/blood-2016-01-643569 Swerdlow SH Campo E Pileri SA Harris NL Stein H Siebert R Advani R et al Blood The 2016 revision of the World Health Organization classification of lymphoid neoplasms 4 12 179-188 12 2019 10.1016/j.hemonc.2019.05.002 Advani P Paulus A Ailawadhi S Hematology/Oncology and Stem Cell Therapy Updates in prognostication and treatment of Waldenström's macroglobulinemia 1 01 214-226 18 2000 10.1200/JCO.2000.18.1.214 Dimopoulos MA Panayiotidis P Moulopoulos LA Sfikakis P Dalakas M Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology Waldenström's macroglobulinemia: clinical features, complications, and management 3 12 575-582 115 2001 10.1046/j.1365-2141.2001.03144.x García-Sanz R Montoto S Torrequebrada A Coca AG Petit J Sureda A Rodríguez-García JA et al British Journal of Haematology Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases 5 05 252-262 17 2017 10.1016/j.clml.2017.02.028 Yun S Johnson AC Okolo ON Arnold SJ McBride A Zhang L Baz RC Anwer F Clinical Lymphoma, Myeloma & Leukemia Waldenström Macroglobulinemia: Review of Pathogenesis and Management 4 08 645-648 174 2016 10.1111/bjh.13794 Castillo JJ Kanan S Meid K Manning R Hunter ZR Treon SP British Journal of Haematology Rituximab intolerance in patients with Waldenström macroglobulinaemia 5 05 1104-1113 57 2016 10.3109/10428194.2015.1096357 Cao X Medeiros LJ Xia Y Wang X Thomas SK Loghavi S Li X et al Leukemia & Lymphoma Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression 5 10 811-820 32 2018 10.1016/j.hoc.2018.05.008 Castillo JJ Treon SP Hematology/Oncology Clinics of North America Initial Evaluation of the Patient with Waldenström Macroglobulinemia 177-195 165 2015 10.1007/978-3-319-13150-4_7 Castillo JJ Ghobrial IM Treon SP Cancer Treatment and Research Biology, prognosis, and therapy of Waldenström Macroglobulinemia 11 11 e446-449 100 2015 10.3324/haematol.2015.124149 Kastritis E Kyrtsonis M Morel P Gavriatopoulou M Hatjiharissi E Symeonidis AS Vassou A et al Haematologica Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy 3 09 420-428 116 2001 10.1309/4LCN-JMPG-5U71-UWQB Owen RG Barrans SL Richards SJ O'Connor SJ Child JA Parapia LA Morgan GJ Jack AS American Journal of Clinical Pathology Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors 01 18 05 2791-2796 123 2014 10.1182/blood-2014-01-550905 Treon SP Cao Y Xu L Yang G Liu X Hunter ZR Blood Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia 10 vi155-159 24 Suppl 6 2013 10.1093/annonc/mdt298 Buske C Leblond V Dimopoulos M Kimby E Jäger U Dreyling M Annals of Oncology: Official Journal of the European Society for Medical Oncology Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 01 9 09 1257-1265 3 2017 10.1001/jamaoncol.2016.5763 Kapoor P Ansell SM Fonseca R Chanan-Khan A Kyle RA Kumar SK Mikhael JR et al JAMA oncology Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016 8 08 1417-1425 97 2018 10.1007/s00277-018-3311-z Paludo J Abeykoon JP Shreders A Ansell SM Kumar S Ailawadhi S King RL et al Annals of Hematology Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia 10 11 09 1392-1394 126 2015 10.1182/blood-2015-05-647420 Kastritis E Gavriatopoulou M Kyrtsonis M Roussou M Hadjiharissi E Symeonidis A Repoussis P et al Blood Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study 01 22 08 3344-3349 25 2007 10.1200/JCO.2007.10.9926 Dimopoulos MA Anagnostopoulos A Kyrtsonis M Zervas K Tsatalas C Kokkinis G et al Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide 1 01 132-138 16 2005 10.1093/annonc/mdi022 Treon SP Emmanouilides C Kimby E Kelliher A Preffer F Branagan AR Anderson KC Frankel SR Annals of Oncology: Official Journal of the European Society for Medical Oncology Extended rituximab therapy in Waldenström's macroglobulinemia 09 15 04 1430-1440 372 2015 10.1056/NEJMoa1501548 Treon SP Tripsas CK Meid K Warren D Varma G Green R et al The New England Journal of Medicine Ibrutinib in previously treated Waldenström's macroglobulinemia 2 02 241-250 18 2017 10.1016/S1470-2045(16)30632-5 Dimopoulos MA Trotman J Tedeschi A Matous JV Macdonald D Tam C Tournilhac Ol et al The Lancet. Oncology Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial 73-83 9 2017 10.2147/CMAR.S94059 Abeykoon JP Yanamandra U Kapoor P Cancer Management and Research New developments in the management of Waldenström macroglobulinemia 01 4 05 40 8 2018 10.1038/s41408-018-0076-5 Gertz MA Blood Cancer Journal Waldenström macroglobulinemia treatment algorithm 2018 27 3 03 e394 5 2015 10.1038/bcj.2015.28 Oza A Rajkumar SV Blood Cancer Journal Waldenstrom macroglobulinemia: prognosis and management 05 1 12 125-134 2014 2014 10.1182/asheducation-2014.1.125 Wiestner A Hematology. American Society of Hematology. Education Program BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma 01 13 07 2230-2236 121 2015 10.1002/cncr.29334 Castillo JJ Olszewski AJ Hunter ZR Kanan S Meid K Treon SP Cancer Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database